Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD

Journal of the American Society of Nephrology

Volumn 25, Issue 3, 2014, Pages 431-442

  Harel, Ziv ^a   Sholzberg, Michelle ^b   Shah, Prakesh S ^c   Pavenski, Katerina ^b   Harel, Shai ^a   Wald, Ron ^a   Bell, Chaim M ^c   Perl, Jeffrey ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; ELEQUIS; RIVAROXABAN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; META ANALYSIS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84895452890     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013040361     Document Type: Review

References (46)

1. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial InvestigatorsRE-SONATE Trial Investigators: Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368: 709-718, 2013
2. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators: Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 76: 2104-2111, 2012
3. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499-2510, 2010
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891, 2011
5. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992, 2011
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
7. Yeh CH, Fredenburgh JC, Weitz JI: Oral direct factor Xa inhibitors. Circ Res 111: 1069-1078, 2012
8. Ezekowitz MD, Nagarakanti R: Dabigatran in atrial fibrillation: Pharmacology and clinical trials. J Interv Card Electrophysiol 32: 173-180, 2011
9. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA: Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 8: 569-578, 2012
10. Harder S: Renal profiles of anticoagulants. J Clin Pharmacol 52: 964-975, 2012
11. Nelson SE, Shroff GR, Li S, Herzog CA: Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc 1: e002097, 2012
12. Mahmoodi BK, Gansevoort RT, Næss IA, Lutsey PL, Brækkan SK, Veeger NJ, Brodin EE, Meijer K, Sang Y, Matsushita K, Hallan SI, Hammerstrøm J, Cannegieter SC, Astor BC, Coresh J, Folsom AR, Hansen JB, Cushman M: Association of mild to moderate chronic kidney disease with venous thromboembolism: Pooled analysis of five prospective general population cohorts. Circulation 126: 1964-1971, 2012
13. FDA approved drug products: label information for PRADAXA. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 022512s009lbl.pdf. Accessed January 16, 2013.
14. FDA approved drug products: Xarelto. 2012. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022406s001s002s003lbl.pdf. Accessed January 16, 2013.
15. FDA approved drug products: Eliquis. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202155s000lbl. pdf. Accessed January 16, 2013.
16. Health Canada: Drugs and Health Products: Pradax. 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2008-pradax- 114887-eng. php. Accessed January 16, 2013.
17. Health Canada: Drugs and Health Products: Xarelto. 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2009-xarelto- 119111-eng.php. Accessed January 16, 2013.
18. Health Canada: Drugs and Health Products: Eliquis. 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2012-eliquis- 141873-eng.php. Accessed January 16, 2013.
19. Fellows SE, Rosini JM, Curtis JA, Volz EG: Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med44: e221-225, 2013
20. Wychowski MK, Kouides PA: Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 46: e10, 2012
21. Boehringer-Ingelheim. Interim results from RELY-ABLE®, the RE-LY® extension study, provide additional clinical evidence for the safety of Pradaxa® (dabigatran etexilate mesylate). 2012. Accessed at: http://us.boehringer-ingelheim.com/news-events/press-releases/ press-release-archive/2012/ 11-07-12-interim-results-rely-able-re-ly-extension- study-clinical-evidence-safety-pradaxa-dabigatran-etexilate-mesylate.html. Accessed January 16, 2012.
22. Schulman S, Kakkar AK, Schellong SM, et al: A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [Abstract]. Blood 118: 2011
23. Ogawa S, Shinohara Y, Kanmuri K: Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J 75: 1852-1859, 2011
24. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342-2352, 2009
25. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN-PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287-1297, 2012
26. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A: Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 345: e7498, 2012
27. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr: Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: A systematic review. Ann Intern Med 157: 796-807, 2012
28. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W: Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation 126: 2381-2391, 2012
29. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ: Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110: 453-460, 2012
30. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118: 2029-2037, 2008
31. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ: Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: A record linkage study in a large British population. Heart 91: 472-477, 2005 (Pubitemid 40432773)
32. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L: Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 33: 2821-2830, 2012
33. Capodanno D, Angiolillo DJ: Antithrombotic therapy in patients with chronic kidney disease. Circulation 125: 2649-2661, 2012
34. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY: Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 60: 861-867, 2012
35. Kernan L, Ito S, Shirazi F, Boesen K: Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) 50: 571-573, 2012
36. Mack DR, Kim JJ: Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Ann Pharmacother 46: 1105-1110, 2012
37. Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, Berglund EG, Pang KS, Rahman A, Zhang L, Lesko LJ, Huang SM: Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: Implications for clinical practice. Biopharm Drug Dispos 33: 99-110, 2012
38. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT: Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5: 1003-1009, 2010
39. Lafrance JP, Djurdjev O, Levin A: Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrol DialTransplant 25: 2203-2209, 2010
40. U.S. Renal Data System: 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available at: http://www.usrds.org/2012/pdf/v1-ch1-12.pdf. Accessed January 16, 2013.
41. Galbusera M, Remuzzi G, Boccardo P: Treatment of bleeding in dialysis patients. Semin Dial 22: 279-286, 2009
42. Siegal DM, Crowther MA: Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 34: 489-498b, 2013
43. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 151: W65-94, 2009
44. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133[Suppl]: 381S-453S, 2008 (Pubitemid 351894916)
45. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: 692-694, 2005
46. Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration. Available at: www. http://handbook. cochrane.org/. Accessed December 26, 2012